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Summary.-The effects of hormone and drug treatments on plasma prolactin (PRL)
levels and mammary tumour growth were investigated in rats bearing continuously
growing DMBA-induced mammary tumours that responded to bilateral adreno-
ovariectomy (Ax+ Ox). Oestrogen (E2) administration increased both plasma PRL
and tumour growth, but was unable to sustain tumour growth when the PRL level
was reduced by concurrent injection of ergocornine (Eg). Perphenazine (P,) produced
a dose-related increase in plasma PRL, but stimulation of tumour growth in the
absence of E2 required a minimal level of plasma PRL induced by Pz (0-15 mg/100 g
body wt/day or more). Progesterone (P) (3 mg/day) alone, although without effect on
PRL levels, maintained static tumour growth (i.e. it had a slight stimulatory effect)
irrespective of the duration of treatment. The increase in plasma PRL levels above
the basal values in the Ax+Ox controls following injections of combined P+P,
(0 1 mg/100 g/day) was sufficient to sustain static tumour growth, but not to
reactivate growth. Enhancement of both plasma PRL and tumour growth did not
occur until P and higher doses of Pz (0.3 mg/100 g/day) were injected jointly; this
treatment, however, while unable to stimulate continuous tumour growth, was able
to maintain static growth when plasma PRL was reduced by concurrent injections
of P+Pz+Eg. From these findings it is postulated that the mechanism of action
whereby P maintains static tumour growth is different from that of PRL and
independent of circulating PRL levels.
THE MAJORITY of rat tumours induced
by 7, 12-dimethylbenz -(a) -anthracene
(DMBA) are hormone-dependent, as shown
by their regression after ovariectomy
(Ox), adrenalectomy (Ax) and hypo-
physectomy (Pearson et al., 1969). Oestro-
gens (E2) and prolactin (PRL) have
been shown to influence the growth of
such tumours (Pearson et al., 1969). The
dose-effect relationship of PRL on mam-
mary tumour growth and the duration of
PRL-induced stimulation of tumour
growth, in the Ax + Ox rat, is a matter
of debate. After Ax + Ox, Nagasawa &
Yanai (1970) reported that resumption
oftumour growth was not only temporary,
but stimulated only on high doses of
PRL, whilst Pearson et al. (1969) found
that low or high doses of PRL were
equally effective. Reported plasma PRL
levels in rats bearing DMBA-induced
mammary cancers is also contradictory,
both normal (Nagasawa et al., 1973) and
raised values having been found (Teller
et al., 1977).
Although progesterone (P) enhances in-
duction of DMBA tumours (Jabara, 1967)
its role in the growth of established
tumours is unclear and conflicting. Hor-
witz & McGuire (1977) demonstrated that
P alone failed to sustain tumour growth
after Ax + Ox, despite the initial presence
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of P receptor (i.e., their results suggested
that E2 is an absolute necessity at the
tumour site). Kelly et al. (1977), on the
other hand, reported a similar effect of
P, even though the level of E2 was still
appreciable, but lowered, by Ox.
The present experiments were designed
to clarify the above findings by determin-
ing the effects and mechanisms of action
of (i) P, (ii) PRL, induced by perphenazine
(Ps) and (iii) P+P,, on the growth of
DMBA-induced mammary carcinomas and
on plasma PRL levels in Ax + Ox rats.
MATERIALS AND METHODS
Treatment of animals.-Two hundred and
twenty virgin female random-bred Sprague-
Dawley rats, weighing 120 + 20 g and fed
commercial pellets and tap water ad libitum,
were housed 5 rats/cage. At 50 days of age,
they each received a single intragastric dose
of30 mg DMBA (Eastman Organic Chemicals,
U.S.A.) dissolved in 2 ml maize oil. Beginning
4 weeks after DMBA administration, all rats
were palpated weekly and any mammary
tumour recorded, measured and graphed as
described previously (Jabara, 1967). Rats
bearing at least one continuously growing
tumour were allocated randomly to one of 6
groups (Table I). A tumour was designated as
"growing continuously" if the size of the
neoplastic mass steadily increased during the
course of at least 5 weekly measurements.
When these tumours had reached a diameter
of ' 2 cm, the rats were weighed and given
bilateral Ax+Ox. Thereafter they had access
to both saline (0-9%) and tap water, and
received s.c. injections of deoxycortico-
sterone acetate (Calbiochem, N.S.W.), 0-1 mg/
100 g body weight/2 days, dissolved in 0-1 ml
maize oil, to assist sodium retention. When
the continuously growing tumours had re-
gressed to half their original preoperative
size (14 days on average) (Figs 1-4) the rats
were injected s.c., once daily, with oestradiol-
17f (E2) (Calbiochem, N.S.W.), progesterone
(P) (Sigma Chemical Co., U.S.A.), perphen-
azine (Pz) ("Trilafon", Schering Corp.,
U.S.A.), ergocornine hydrogenmaleinate (Eg)
(Sandoz, Switzerland) or combinations, in the
doses and for the periods shown in Table I.
P and E2 were dissolved in maize oil, P, in
0-9% saline and Eg in 15% ethanol made up
with 0-9% saline. Daily vaginal smears were
taken at about 09:00 from all rats in Group 1,
to ensure that the animals remained in an
oestrus-like state.
Following Ax+Ox, the skin over each
tumour was kept shaved and each neoplasm
was measured and graphed twice weekly
until the end of the experiment. At necropsy
each rat was weighed, and portions of each
mammary tumour were labelled as to site
and side, fixed in 10% buffered formalin and
5,um paraffin sections were stained with
haematoxylin and eosin.
Blood sampling and PRL assay.-As ether
anaesthesia has been shown to increase
serum PRL levels in experimental animals
(Linke & Niswender, 1972), each rat was
etherized for a standard period of 40 sec
before 0 4 ml of blood from the caudal vein
was collected into heparinized tubes, just
before a particular hormone injection, and at
various times between 1 and 30 days after-
wards. The blood was centrifuged at 1100 g
for 10 min, and the plasma stored at - 20°C
until PRL levels were assayed.
Plasma PRL was measured by the radio-
immunoassay method supplied with the
NIAMD kit, with only minor modifications.
Duplicates were run for each sample and,
in order to avoid interassay variation,
samples from a complete experiment were
assayed at the same time. Results were ex-
pressed in terms of the NIAMD-Rat Pro-
lactin-RP-1 standard supplied with the kit.
Statistical analysis.-Thepatternsofgrowth
of the mammary carcinomas were calculated
from the slopes for the regression lines for
individual rats under similar treatments, by
the method described by Rees & Westwood
(1974), except that the present data did not
require a logarithmic transformation of the
results, as they fitted straight lines. Com-
parison of the growth characteristics of 2
treatment groups was made by comparing
the common slope for each group by t test. A
common slope for the regression lines for rats
under similar treatments can be justified by
an analysis of variance for all points for all
rats under that treatment. A pooled estimate
for this slope was used in the calculations
(Armitage, 1971).
Comparison of the mean serum prolactin
concentrations between different treatments
was made by t test, the correlation co-
efficients being computed in the standard
manner (Schefler, 1969).
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RESULTS
Tumour incidences
Of 220 rats fed DMBA, 194 (88%) sur-
vived the initial toxic effects of the
carcinogen and 153 (79%o) of these de-
veloped mammary tumours after an
average latent period of 86 days. Fifty
(330%) rats bearing neoplasms showed a
continuous growth pattern for at least one
of their tumours, and only 40 (79%o) of
these responded to Ax +Ox by a marked
regression in their size, indicating their
hormone-dependence. Only these hor-
mone-responsive neoplasms were used in
the present experiments.
Effects oftreatments on survival ofrats
E2, P and Eg treatments administered
at the doses stated in Table I did not
affect the survival of rats in Groups 1 and
2. The lowest dose of P, (0-1 mg/100 g/
day) also caused no noticeable change in
TABLE I.-Hormone and drug regimes
administered to 6 groups of bilaterally
adreno-ovariectomized rats bearing parti-
ally regressed DMBA-induced mammary
carcinomas
Group Treatmenit
I E2
E2+Eg
2 I'
PXA
Dose
(rng/ 100 g/day)
(-0015*
0-0015*+0-1 5
3*
:3*
3 ,., 01
PZXA O
4 )+P., 3*+0-1
5 P,z 0-3
£PZXA 0
PZ 003
PZ+P 0.3+3*
Pz+P+Eg 0-3+3*+0-15
6 PZ 0-15
PZ 0020 PZ 0-25
PZ 0030 PZ 0 40
P, 0050
* Dose admitistered as mg/day.
A "X" indicates cessation of treatment.
behaviour or appearance of the rats in
Groups 3 and 4. Doses higher than this
(Groups 5 and 6) caused drowsiness or
stupor and weight loss, and only I10% of
the rats receiving daily doses of P, be-
tween 0-15 and 0 5 mg/100 g survived
up to 10 days. Combined P +P,
administration to rats in Group 5 counter-
acted the loss in body weight observed
with P, only (0-3 mg/100 g/day) but the
sedative effect of P, appeared to make
them more susceptible to infection, result-
ing in several deaths from pneumonia.
Effects ofhormones and drugs on miammary-
cancergrowth
Adreno-ovariectomy caused a marked
regression in the size of continuously
growing neoplasms (P < 001). E2 induced
reactivation of tumour growth (P < 0.01),
whereas E2+ Eg decreased the size of
these neoplasms (P < 0 01).
Injections of P (3 mg/day for 30 days),
in contrast, failed to reactivate tumour
growth afterAx + Ox (Fig. 1). The tumours
regressed rapidly, however, when P injec-
tions were discontinued (P < 0.01) and
remained static upon resumption of the
P regime (Fig. 1). Similarly, daily injec-
tions of P, (0-1 mg/100 g) or combined
P +P, treatment to Groups 3 and 4,
respectively, did not reactivate tumour
growth (Figs. 2 and 3); the tumours re-
gressed further after withdrawal of the
P, regime in Group 3 (P < 0.05) (Fig. 2).
Doses of Pz>0I mg/100 g/day in-
creased the tumour growth rate in pro-
portion to the dose (Table II). This corre-
lation was significant (P < 0 001) within
the limitations of the data, the rats so-
treated only surviving between 4 and 10
days (Table II). Of particular interest
was the finding that combined P+Pz
(0.3 mg/100 g/day) treatment to animals
in Group 5 gradually increased their
tumour sizes over 21 days, but the addi-
tion of Eg to this combination appeared
to revert the neoplastic growth pattern
to a static one (Fig. 5) for at least 7 days
(the rats died at this point).
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FIG. 1. Effects of progesterone (P) on growth of mammary tumours from 3 rats in Group 2 (Li) and
their mean plasma prolactin levels (±s.d.) (U).
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FIG. 2.-Effeets ofperphenazine (Pt) on growth of mammary tumours from 6 rats in Group 3 (DO) an(d
their mean plasma prolactin levels (± s.d.) (*).
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FIG. 3. Effects of progesterone (P) and progesterone +perphenazine (P+P,) on growth of
mammary tumours from 6 rats in Group 4 (Lin) and their mean plasma prolactin levels (± s.d.) (*).
TABLE II. Effects of various perphenazine (Pz) doses on tumour size, plasma prolactin
(PRL) levels and survival ofbilaterally adreno-ovariectomized (Ax+Ox) DMBA-induced
mammary tumour-bearing rats of Group 6
Tumour size (cm)
At start
Rat P, dose At of Pz At Increase
No. (mg/100 g/day) Ax + Ox treatment* death per dayt
2
3
4
5
6
7
8
9
10
11
0-15
0-15
0-20
0-20
0-25
0-25
0-30
0-30
0 40
0-50
0-50
1-6
1-7
1-6
1-6
1-9
1-7
2-1
1-9
1-6
2-1
1-75
0-8
0-85
0-8
0-8
0.95
0-85
1-05
0-95
0-8
1-05
0-9
1-0
1-4
1-4
1-4
1-35
1-35
1-5
1-72
1-2
2-1
1-5
0-05
0-05
0-06
0-07
0 07
0-07
0-09
0-11
0-10
0-12
0-12
Plasma PRL
(nig/ml +s.d.)4:
Time after
treatment (days)
Survival .
(days)t 1 7
4
10
10
9
6
7
5
7
4
8
5
77+2
110+7
110+7 155+3
153 + 8
281+ 5
215 + 6
328 + 11
355 + 22
556 + 9
463 + 20
* 15 +1 days after Ax + Ox.
t From start of P, treatment until death.
t PRL was assayed in duplicate.
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Effects of hormone and druy treatments on
plasma prolactin levels
Fifteen days' treatment with E2 in-
creased the plasma prolactin (PRL) con-
centration (P < 0001) above the level in
the Ax + Ox control group (112 + 5 4 ng/
ml). Administration of Eg+ E2 to these
rats significantly depressed the plasma
PRL to Ax+Ox levels (P<0001). In
contrast, P treatment did not alter the
plasma PRL significantly from Ax + Ox
levels, irrespective of the duration of its
administration (Fig. 1). P, (0 1 mg/lOO g/
day) increased the concentrations mar-
kedly above Ax + Ox levels (P < 0.05)
(Fig. 2). Cessation of P, injections led to
a significant reduction in PRL level
within 24 h (P < 0-001) decreasing to Ax +
Ox levels by 21 days (Fig. 2) Combined
P +P, injections for 24 h to animals in
Group 4 significantly increased the PRL
levels above those observed when P
(P<001) and Pz (P<001) were each
administered singly for 24 h, and also
Ax+Ox Pz N?PZ
w51~~$ N1P LU
cr 2
w
above Ax + Ox control values (P < 0.01)
(Fig. 3). A gradual but significant rise in
the PRL levels was observed after 15
(P<001) and 30 days (P<001) respec-
tively after combined P+P,, which were
above those obtained at similar intervals
after treatment with either hormone alone
(Fig. 3).
Increasing the daily dose of P, to
0 3 mg/lOO g significantly raised the
plasma PRL levels both above Ax +Ox
controls (P < 0-01) and above that of
Group 3 (04 mg/I00 g/day P,) (P <001)
24 h after injection (Fig. 4). This value
did not alter significantly 24 h after
cessation of P, treatment, but was de-
creased markedly 15 days later (P < 0.05).
Rats in Group 5 showed significantly
raised PRL levels 15 days after resump-
tion of P, treatment (P < 0 02). Simul-
taneous injection of P markedly increased
the concentration of PRL, after 10 days
(P < 0 05) and 21 days (P <001) respec-
tively, when compared with the values
Pz P4jPZ P+PZ+Eg
-400
-300
CD
200
1003'
110 120 130 140 150 160 170 180 190 200 DAYS
Ft(,. 4. Effects of perplienazine (Pz), P +Pz and P +P, +ergocornine (Eg) on growth of mammarv
tumours from 2 rats in Grouip 5 (3) and tlieir mean plasma prolactin levels (± s.d.) (l).
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before P treatment; however, the mean
increase was only 12%0 compared with
70%0 in Group 4. Administration of Eg to
these animals, in addition to P and Pz,
effectively reduced the PRL levels after
24 h (P < 0.01) and, after 7 days, levels
had returned to Ax+Ox control values
(Fig. 4).
Daily P, doses of 0 1 5-0 5 mg/I 00 g/day
(Table II) all increased the plasma PRL
values in Group 6 above those of the
Ax + Ox controls within 24 h (P < 0.05).
PRL titres were significantly increased in
proportion to the dose of P, (P < 005 in
each case, except for 0 4 mg/100 g/day
P,, which could not be calculated since
only one rat survived).
Correlation between tumour size and plasma
PRL
A significant correlation was shown
between plasma PRL levels and corre-
sponding tumour sizes (Figs. 1-4) in
Groups 1 and 2 and in those animals in
Group 6 which received daily treatments
with 0 15-0-3 and 0 5 mg/100 g P,
(P < 0.05); there also appeared to be a
correlation between tumour size and PRL
value in rats treated with 0 4 mg/I 00 g/day
PZ, but statistical analysis was not possible
as only one animal survived this regime
for long enough. No significant correla-
tions between PRL levels and tumour
sizes were found in Groups 3 and 4, nor in
Group 5,after acombinationof P +P, +Eg.
However, a correlation was apparent in
Group 3 when Pz administration Aras dis-
continued (Fig. 2) and in Group 5 when
only P +Pz was given (Fig. 4).
Tumour types
All neoplasms used in these experiments
were carcinomas. Tumours from animals
in all groups other than Group 5, weighed
up to 3 g and measured up to 1 cm (mean
diameter); neoplasms from rats in Group
5 weighed up to 25 g and measured up to
34 cm (mean diameter). Microscopically,
most mammary neoplasms in all 6 groups
were papillary cystadenocarcinomas, while
a few were classified as adenocarcinomas
or solid, poorly differentiated carcinomas
(Jabara, 1967). No direct correlation was
evident between tumour growth behaviour
and histology of the carcinomas in Groups
1-6 and, apart from marked degenerative
changesin carcinomas after E2 +Eg (Group
1), there was no apparent relationship
between tumour histology and treatment
of the host in any of the 6 groups of
animals.
DISCUSSION
In agreement with previous findings
(Pearson et al., 1969) E2 administration
caused a significant increase in plasma
PRL, and also reactivated growth of
tumours which had regressed after Ax+
Ox. Subsequent concurrent injections of
E2 + Eg induced macroscopic regression
of these E2-dependent tumours, gross
degenerative histological changes in the
neoplasms, and markedly reduced plasma
PRL levels (Shaar & Clemens, 1972).
The observation that P, produced a
dose-related increase in plasma PRL
confirms the findings of Bogden et al.
(1974). Perphenazine is thought to raise
plasma PRL levels by inhibiting dopa-
minergic transmission, either through sup-
pression of hypothalamic PRL-inhibitory
factor, or antagonism of that factor at the
level of the pituitary, or both (Frantz,
1.978). However, it is interesting to note
that in the present experiment no increase
in growth of otherwise static, hormone-
responsive tumours was apparent unless
P, was administered in doses of 0 1 5 mg/
100 g/day or more. In other words, a low
dose of prolactin (i.e. 0 1 mg/100 g/day)
was insufficient, to reactivate tumour
growth, but was able to maintain static
growth by slightly stimulating the tumour
in order to sustain growth in the static
phase. Active growth, on the other hand,
appeared to require a certain minimal
level ofplasma PRL, as was also suggested
from the work of Nagasawa & Yanai
(1970). They demonstrated that injections
of ovine PRL (1.25 mg, twice daily for 20
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days) to Ax + Ox rats bearing DMBA-
induced mammary carcinomas, reactivated
growth of the tumours only for the first
10 days, after which the neoplasms
regressed; injection of the same dose of
PRL 20 days after Ax + Ox had no effect
on tumour growth. Enhancement of both
the level of plasma PRL and of tumour
growth up to 14 days from the start of
injections did not occur until higher doses
ofPz (0 3 mg/I00 g/day) were administered
in accord with the findings ofNagasawa &
Yanai (1970). However, the duration of
PRL-induced stimulation of tumour
growth did not appear to be limited.
Whether the tumours became so large as
to render growth autonomous (Griswald
& Green, 1970; Huggins & Yang, 1962) or
whether growth simply cannot be sus-
tained (Nagasawa & Yanai, 1970; Klaiber
et al., 1969) beyond 14 days needs to be
studied further, especially the effects of
Pz at doses >0(15 mg/100 g/day and for
longer periods. Unfortunately, this was
not possible in the present experiments
because, in contrast to the findings of
Pearson et al. (1969), high mortality was
observed when Pz doses exceeded 0 1 mg/
100 g/day; this may be due to the sub-
strain of Sprague-Dawley rat used in the
present experiments being more suscept-
ible to this drug.
The present findings, as well as those
of Nagasawa & Yanai (1970), are in direct
contrast to reports by Sinha et al. (1973)
which suggest that PRL alone, in the
absence of E2, is insufficient to maintain
growth of DMBA-induced tumours,
ovarian hormones being necessary to
maintain the sensitivity of the tumour to
the PRL effect. The present results may be
explained if prolactin is assumed to amp-
lify its own receptor levels in the mam-
mary gland, as suggested by Djiane &
Durand (1977). Furthermore, breast can-
cers contain a heterogeneous cell popula-
tion within a single tumour, and among
different tumours, anditisconceivablethat
the rate of tumour growth in response to a
particular hormone (e.g. PRL) might de-
pend on the rate of cell division of PRL-
57
dependent cells within it. It may be
postulated, therefore, that the high dose
of P, (0.3 mg/100 g/day) would increase
the level of plasma PRL and the number
of PRL receptors, and hence cause a far
greater increase in the rate of division
of existing PRL-dependent cells than
would a low dose ofP. (041 mg/100 g/day)
which only maintained static tumour
growth (i.e. a growth pattern which
requires an equilibrium between cell gain
and cell loss).
Progesterone alone, though without
effect on PRL levels, was found to main-
tain static tumour growth (i.e. it exerted a
slight stimulatory effect on the tumour to
sustain growth in a static phase). Kim
(1965) also reported a similar effect of P
on 3-methylcholanthrene-induced mam-
mary tumours. P may possibly have some
direct metabolic effect on the growth of
these tumours, growthper se not appearing
to be the important factor, but rather the
biochemical consequence(s) of P. In any
event it is interesting to note that P acts
independently of circulating plasma PRL.
Therefore the present findings indicate
that P apparently acts by a different
mechanism from PRL to maintain static
growth, especially in view of the fact that
P+P, high-dose treatment caused an
additive increase in circulating PRL
levels. It is postulated that P may be
acting directly at the tumour site (Asselin
et al., 1976) by inducing the synthesis of
sufficient P receptor to maintain, but not
increase, tumour growth. More extensive
studies are needed, especially in the field
of P receptors and the mapping of the
complex sequence of events which accom-
pany receptors, to evaluate this concept
further. However, it seems unlikely that
P is acting via an effect on PRL secretion
since, despite basal Ax + Ox control PRL
levels recorded after P and P+Pz+Eg
treatments (Groups 2 and 5, respectively),
tumour growth remained static and did
not regress as would have been expected
if PRL were involved. In addition, the
hypothesis that E2 is mandatory for
tumour growth cannot be supported by
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the present data, because 14 days after
Ax+ Ox, when plasma E2 levels would be
expected to be minimal, it was noted that
(i) high doses of P, were effective in
markedly increasing tumour growth, and
(ii) tumour growth remained static after
P and P+Pz+Eg treatments. The first
observation of this series is in agreement
with that of Leung et al. (1975), who
found that PRL stimulated the growth of
some endocrine-ablation-responsive tu-
mours 7 or 11 days after Ax+Ox, but
required E2 as well to stimulate others.
The second observation contrasts with
the report by Horwitz & McGuire (1977)
and even more so with that of Kelly et al.
(1977), whose finding that P cannot
maintain tumour growth after Ox in the
presence of low but appreciable levels of
plasma E2 is puzzling. Furthermore, the
fact that rats receiving 3 mg P daily
remain in almost continuous dioestrus
(Jabara et al., 1972) fails to confirm the
suggestion of Baggett et al. (1956) that P
may be converted to E2 in vivo.
This study does not negate the impor-
tance of PRL and E2 in the growth of
DMBA-induced mammary neoplasms, but
suggests that alongside these hormones P
may also play a vital part in the promo-
tional stage of mammary carcinogenesis.
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